cetylpyridinium chloride anhydrous has been researched along with dasatinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, J; Han, X; Kantarjian, H; Quintás-Cardama, A | 1 |
1 other study(ies) available for cetylpyridinium chloride anhydrous and dasatinib
| Article | Year |
|---|---|
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Topics: Benzamides; Blood Coagulation; Blood Platelet Disorders; Dasatinib; Health; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |